Press "Enter" to skip to content

Benzos and Pneumonia; Generic Latuda OK’d; Bipolar Brain Protein

Benzodiazepines were tied to pneumonia risk in a review of over 120,000 cases. (International Journal of Geriatric Psychiatry)

The first generic version of lurasidone (Latuda in branded form) received FDA marketing approval, said manufacturer Lupin Pharmaceuticals.

Kids born to woman taking the epilepsy drug valproate in pregnancy had a 48% higher risk for ADHD. (JAMA Network Open/MedPage Today)

People with bipolar disorder tended to have lower levels of the protein CPG2 in their brains. (Molecular Psychiatry)

The investigational drug AEVI-001 — tested in pediatric ADHD patients with and without mGluR copy number variants — failed in the phase 2 ASCEND trial, Aevi Genomic Medicine announced.

A drug-device combination providing intranasal delivery of olanzapine, intended for bipolar and schizophrenia-related agitation, passed a phase I trial, said the maker Impel NeuroPharma. The product sped achievement of peak blood levels faster than either oral or intramuscular olanzapine formulations.

Naltrexone pretreatment followed by ketamine was well tolerated and helped reduce symptoms of depression and alcohol cravings. (JAMA Psychiatry)

There may be benefit in reassessing teens with depression after only 4 weeks of interpersonal psychotherapy rather than after 8 weeks, a study suggested. “If therapists routinely assess depression symptoms over the course of treatment and intervene early, when indicated, to augment treatment, this may improve outcomes,” said lead author Meredith Gunlicks-Stoessel, PhD, of the University of Minnesota in a statement. (Journal of the American Academy of Child and Adolescent Psychiatry)


last updated